EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identifying optimal combination regimens for therapy of Mycobacterium tuberculosis with an algorithmic approach: prospective predictions and validations

Arnold Louie, Michael Neely, Sarah Kim iD, Charles A Scanga, JoAnne L Flynn, Charles A Peloquin iD, Brendan Prideaux, Stephan Schmidt, Mohammed Almoslem, Walter Yamada iD, George Drusano iD

PLOS One · 2026

DOI: 10.1371/journal.pone.0324206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Arnold Louie und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Therapeutic Innovation, University of Florida College of Medicine Orlando, Florida, United States of America. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, Algorithms, Tuberculosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Division of Intramural Research, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mycobacterium tuberculosis resistance to standard-of-care agents is increasing. It is imperative to identify new combinations that increase the rate and depth of bacterial kill, shorten therapy and also suppress resistance. There has been little prior effort to identify combination regimens that employ new or repurposed drugs in a rational way. Methods and Findings Our group developed a pathway to combine agents to achieve this end. This pathway starts with standard baseline evaluations (e.g., MIC), leverages information from in vitro assessments (hollow fiber infection model), then analyzes 2-agent combinations in a 96 well quantitative culture checkerboard format (Greco URSA model with simulation). Finally, development of a high dimensional mathematical model allowed evaluation of 2- and 3-drug regimens in multiple metabolic states to draw inferences regarding combination therapies. We prospectively evaluated these regimens in animal models. We showed that a prospectively chosen regimen of pretomanid, moxifloxacin plus bedaquiline performed as predicted. In the BALB/c murine model, this regimen produced sterilization in a cohort that was held for 12 weeks after therapy cessation, as it did in the C3HeB/FeJ (“Kramnik”) murine model. Finally, this and other regimens were evaluated in a cynomolgus macaque model. The decrement of the 18 F-deoxyglucose signal in Positron emission tomography (PET)- computed tomography (CT) evaluations was best with this regimen. Other endpoints such as necropsy score and colony counts in lung and lymph nodes also demonstrated that this regimen behaved as predicted from our pathway/algorithm.

Conclusions

We conclude that this provides a way forward for the future to identify the most promising regimens to shorten therapy for tuberculosis and suppress emergence of resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisAntitubercular AgentsAlgorithmsTuberculosisAnimalsDrug Therapy, CombinationMoxifloxacinMiceDiarylquinolinesMicrobial Sensitivity TestsNitroimidazolesMice, Inbred BALB CProspective StudiesFemale

Substanzen

Antitubercular AgentsMoxifloxacinbedaquilineDiarylquinolinesNitroimidazolespretomanid

Autor:innen und Institutionen

  • Institute for Therapeutic Innovation, University of Florida College of Medicine Orlando, Florida, United States of America.
  • Laboratory of Applied Pharmacokinetics and Bioinformatics, The Saban Research Institute, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, United State…
  • Department of Pharmaceutics, Center for Pharmacometrics and System Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, United States of America].
  • Department of Microbiology and Molecular Genetics and Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
  • Pharmacotherapy & Translational Research, University of Florida College of Pharmacy, Gainesville, Florida, United States of America.
  • Department of Neurobiology, The University of Texas Medical Branch Galveston, Galveston, Texas, United States of America.

ORCID-Profile: Sarah Kim, Charles A Peloquin, Walter Yamada, George Drusano

Förderung

  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Zitieren

APA

Louie, A., Neely, M., Kim, S., Scanga, C. A., Flynn, J. L., Peloquin, C. A., Prideaux, B., Schmidt, S., Almoslem, M., Yamada, W., & Drusano, G. (2026). Identifying optimal combination regimens for therapy of Mycobacterium tuberculosis with an algorithmic approach: prospective predictions and validations. PLOS One. https://doi.org/10.1371/journal.pone.0324206

Vancouver

Louie A, Neely M, Kim S, Scanga CA, Flynn JL, Peloquin CA, et al. Identifying optimal combination regimens for therapy of Mycobacterium tuberculosis with an algorithmic approach: prospective predictions and validations. PLOS One. 2026. doi:10.1371/journal.pone.0324206

BibTeX
@article{Louie2026,
  author = {Louie, Arnold and Neely, Michael and Kim, Sarah and Scanga, Charles A and Flynn, JoAnne L and Peloquin, Charles A and Prideaux, Brendan and Schmidt, Stephan and Almoslem, Mohammed and Yamada, Walter and Drusano, George},
  title = {Identifying optimal combination regimens for therapy of Mycobacterium tuberculosis with an algorithmic approach: prospective predictions and validations},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0324206}
}
Kostenlos starten →